loading...| Preferred Name |
Zoledronic Acid |
|
| Synonyms |
|
|
| Definitions |
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1699 |
|
| Accepted_Therapeutic_Use_For |
Hypercalcemia of malignancy; Multiple myeloma and metastatic bone lesions from solid tumors; Paget's disease |
|
| ALT_DEFINITION |
A drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. |
|
| CAS_Registry |
165800-06-6 |
|
| Chemical_Formula |
C5H10N2O7P2.H2O |
|
| code |
C1699 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| definition |
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia. |
|
| Display_Name |
Zoledronic Acid |
|
| FDA_UNII_Code |
6XC1PAD3KF |
|
| Has_Salt_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C179531 http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C179478 |
|
| Is_Value_For_GDC_Property | ||
| label |
Zoledronic Acid |
|
| Legacy Concept Name |
Zoledronate |
|
| Maps_To |
Zoledronic Acid |
|
| NCI_Drug_Dictionary_ID |
42507 |
|
| NSC Number |
721517 |
|
| PDQ_Closed_Trial_Search_ID |
42507 |
|
| PDQ_Open_Trial_Search_ID |
42507 |
|
| Preferred_Name |
Zoledronic Acid |
|
| prefixIRI |
NCIT:C1699 |
|
| prefLabel |
Zoledronic Acid |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0257685 |
|
| subClassOf |
http://purl.obolibrary.org/obo/NCIT_C2136 |